Memphasys is an ASX-listed reproductive biotechnology company driven by market needs to provide reproduction and fertility solutions for humans and animals alike
Memphasys is an ASX-listed reproductive biotechnology company driven by market needs to provide reproduction and fertility solutions for humans and animals alike
| Rank | Company | 1 Yr | 5 Yr |
|---|---|---|---|
| 807th | ACDC Metals | 9.84% | 0% |
| 808th | Argo Global Listed Infrastructure | 9.84% | 7.06% |
| 809th | Memphasys | 9.52% | -36.96% |
| 810th | Judo Capital Holdings | 9.5% | 0% |
| 811th | Eureka Group Holdings | 9.44% | 2.84% |
|
NEW ROLE: David Ali, Acting CEO, Executive Director | 01 Aug 2024 |
|
NEW ROLE: Robert Cooke, Non-Executive Chairman, Non-Executive Director | 01 Aug 2024 |
| NEW ROLE: Michael Atkins, Non-Executive Director | 01 Aug 2024 | |
|
NEW ROLE: David Ali, | 30 Oct 2023 |
|
NEW ROLE: Hassan Bakos, | 30 Oct 2023 |
|
NEWS: Tagged in Memphasys to reinvest tax refund in the next generation | 25 Oct 2023 |
|
NEWS: Tagged in Memphasys brings Indian baby dreams alive with Felix | 15 Sep 2023 |
|
NEWS: Tagged in Memphasys franks Japan deal with first Felix order | 14 Aug 2023 |
|
NEWS: Tagged in Memphasys inks deal with global IVF provider Vitrolife | 07 Aug 2023 |
Access to our data for Memphasys is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Memphasys is included in 1 list - Public Companies - non WA.
For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.